Versicherungen

Aviva share price slips again as AI disruption fears hang over insurers ahead of results
···

Aviva-Aktienkurs fällt erneut, da KI-Störungsängste vor Ergebnissen auf Versicherern lasten

Aviva-Aktien fielen am Mittwoch im frühen Londoner Handel um 0,4 % auf 622,6 Pence, nach einem Verlust von 2,95 % am Vortag. Europäische Versicherer stehen unter Druck, nachdem neue KI-Tools wie das von Insurify eingeführte Vergleichsportal Sorgen über verändertes Kundenverhalten ausgelöst haben. Avivas Jahresergebnisse werden am 5. März erwartet.
April 11, 2026

Stock Market Today

  • Genomic Test Could Spare Millions of Breast Cancer Patients Chemotherapy, Landmark Study Finds
    May 29, 2026, 8:16 PM EDT. A landmark study reveals that millions of breast cancer patients could safely skip chemotherapy thanks to the Prosigna genomic test, which analyses tumor genes to assess recurrence risk. The international OPTIMA trial, involving 4,429 patients, showed a 93.7% five-year cancer-free survival rate for those who avoided chemotherapy, nearly matching the 94.9% rate for those treated with it. Karen Bonham, a trial participant, described her relief upon learning she would not need chemotherapy, attributing her cancer-free status nine years post-diagnosis to the test's guidance. Experts hail the findings as gamechanging, potentially transforming breast cancer treatment by reducing unnecessary chemotherapy and its side effects, while maintaining patient safety.